Le Bao, Yang Seung Hwan
Department of Biotechnology, Chonnam National University, Yeosu, 59626, Republic of Korea.
Toxicol Rep. 2018 Mar 2;5:314-317. doi: 10.1016/j.toxrep.2018.02.007. eCollection 2018.
The incidence of inflammatory bowel disease (IBD) is increasing globally. Altered gut bacteria and bacterial metabolic pathways are two important factors in the initiation and progression of IBD. is distributed in a variety of ecological niches, has a proven ability to survive gastric transit, and can colonize the intestinal tract of human and other mammals. Several studies have described the effects of consumption on human physiology. This review summarizes the safety and the effects of and in animal models for the prevention and management of IBD. modulates the ratio of Th1 and Th2 cells by stimulating the production of different inflammatory cytokines such as tumor necrosis factor-alpha, interleukin (IL)-1β, IL-6, IL-10, IL-12, and interferon-gamma. The blocking of cyclooxygenase-2 in Th1 also is an apoptotic inhibition mechanism. This overview of the molecular studies addresses the activity of in the human gut environment and its' potential for remission of IBD.
炎症性肠病（IBD）在全球的发病率正在上升。肠道细菌和细菌代谢途径的改变是IBD发生和发展的两个重要因素。[细菌名称]分布于多种生态位，已证实其具有在胃内转运中存活的能力，并能在人类和其他哺乳动物的肠道中定殖。多项研究描述了[细菌名称]摄入对人体生理的影响。本综述总结了[细菌名称]在动物模型中预防和管理IBD的安全性及作用。[细菌名称]通过刺激不同炎症细胞因子如肿瘤坏死因子-α、白细胞介素（IL）-1β、IL-6、IL-10、IL-12和干扰素-γ的产生来调节Th1和Th2细胞的比例。Th1中环氧合酶-2的阻断也是一种凋亡抑制机制。这篇分子研究综述探讨了[细菌名称]在人体肠道环境中的活性及其缓解IBD的潜力。
